Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | NPY1R | P25929 | 1/20 | 0.98 |
| ▸ | NPY2R | P49146 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.82 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL19211129 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL41104 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL1649321 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL29367290 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| (S)-Metoprolol SCHEMBL141366 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL29995613 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL4881939 | 0.99 | TDP1 (1.00) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL4879331 | 0.97 | TDP1 (0.96) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| Metoprolol SCHEMBL28264735 | 0.96 | TDP1 (0.94) | TDP1NPY1RNPY2RPMP22NPSR1 | |
| (S)-Metoprolol SCHEMBL3123844 | 0.92 | ADRB2 (0.88) | TDP1NPY1RNPY2RPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-7507545-B2 | Ion channel modulating activity method | CARDIOME PHARMA CORP. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-20060199848-A9 | Cardiovascular disorders; antiarrhythmai agenst; sodium channel moderators; potassium channel moderators; prevent fibrillation | CARDIOME PHARMA CORP. (CA) | 2006-09-07 | — | — | US | disclosed |
| US-20060135536-A9 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2006-06-22 | — | — | US | disclosed |
| US-20050119315-A1 | Ion channel modulating activity II | CARDIOME PHARMA CORP. (CA) | 2005-06-02 | — | — | US | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| WO-2005018635-A2 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119315-A1 | Ion channel modulating activity II | KCNH1, KCNN3, KCNJ2 | ADRB1 265/4885TDP1 2796/4885NPY1R 2695/4885 |
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | ADRB1 329/4885TDP1 1456/4885NPY1R 3572/4885 |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | KCNN1, KCNN3, KCNH1 | ADRB1 329/4885TDP1 1456/4885NPY1R 3572/4885 |
| US-20060199848-A9 | Cardiovascular disorders; antiarrhythmai agenst; sodium channel moderators; potassium channel moderators; prevent fibrillation | KCNN3, KCNN1, KCNN2 | ADRB1 241/4885TDP1 1821/4885NPY1R 2446/4885 |
| US-20060135536-A9 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | ADRB1 329/4885TDP1 1456/4885NPY1R 3572/4885 |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNN2 | ADRB1 258/4885TDP1 2827/4885NPY1R 2806/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | ADRB1 265/4885TDP1 2796/4885NPY1R 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.